• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Regentis raises $10 million in Series C financing

Regentis raises $10 million in Series C financing

May 14, 2012
CenterWatch Staff

Regentis Biomaterials, a privately held company of Princeton, N.J., focused on developing proprietary hydrogels for tissue regeneration, has raised $10 million in its latest round of funding.

The Series C round of financing will be used to establish Regentis' European presence and expand its ongoing clinical efforts of Gelrin—a biodegradable implant that enhances growth of articular cartilage in damaged knee joints. Gelrin is currently an investigational device, and not available for sale in the U.S., Europe or Israel.

"We are thrilled with our new and existing investors' commitment to make Gelrin available to patients suffering from knee cartilage injuries," said Alastair Clemow, CEO and president of Regentis Biomaterials. "With this new investment, Regentis is poised to expand its clinical efforts and further demonstrate how Gelrin can regenerate cartilage so patients can return to an active lifestyle."

Gelrin allows knee cartilage to regenerate, ensuring high quality and a tight fit with surrounding cartilage and underlying bone. It also closely restores cartilage to the condition it was in prior to injury. While there are cartilage repair techniques that relieve pain and restore the knee's functionality, the regenerated cartilage resulting from these procedures is different in nature from the native cartilage and is often followed by subsequent surgical procedure.

Regentis is currently conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of Gelrin. Prior pre-clinical studies have successfully demonstrated its ability to regrow cartilage.

Investors in the Series C financing include Royal DSM through its venturing subsidiary, Crossroad Fund, Medica Venture Partners, SCPVitalife and the Technion Investment Opportunities Fund.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing